Posted by Michael Wonder on 03 Nov 2024
Protega Pharmaceuticals receives FDA approval for Roxybond (oxycodone hydrochloride) immediate release 10 mg tablet with abuse deterrent technology for management of pain
29 October 2024 - Patented SentryBond technology, a first of its kind abuse deterrent technology, is designed to provide multiple levels of protection and has the potential to be utilised in other medications.
Protega Pharmaceuticals announced today that the US FDA has approved Roxybond (oxycodone hydrochloride) immediate release CII 10 mg tablet for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
